INTRODUCTION AND OBJECTIVES: Focal therapy using High Intensity Focused Ultrasound (HIFU) in the treatment of nonmetastatic prostate cancer has been shown to confer a low risk of genitourinary side-effects with encouraging early disease control. We present our single centre experience over a 7 year period (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) of 164 cases. Here we report on medium term functional and oncological outcomes in this group of patients.
METHODS: 164 patients with (T1c-T3a) localised prostate cancer were treated with focal-HIFU. Multi-parametric MRI followed by transperineal mapping biopsies and/or MR-targeted biopsies was used as the standard diagnostic tool. Focal-HIFU was carried out according to disease location and Surgeon planning but usually involved a hemi or quadrant ablation. Patient follow up included regular PSA, MRI and further prostate biopsies if indicated.
RESULTS: 32 (20%), 117 (71%) and 15 (9%) had low, intermediate and high-risk disease, respectively. Median PSA at diagnosis was 7 (range 2.6-21.4). Median follow-up was 50 (range 2-78) months. 100% of patients who were pad free prior to treatment maintained pad free status by 3 months post procedure while 82% of patients who was had satisfactory pre-operative erection maintained their potency postoperatively. There were no major complications and 1 developed a stricture which required intervention. Median PSA nadir was 1.2ng /L by 4.5 months. 7 patients had a further focal-HIFU treatment, whilst 5 had radical prostatectomy and 1 had Radiotherapy. 1 patient underwent cryotherapy and 1 HIFU for contralateral disease. 1 patient required systemic hormones for metastatic disease. Metastasis-free survival and overall cancer specific survival at 5 years was 99.4% and 100% respectively.
CONCLUSIONS: Our single centre focal HIFU experience supports the place for a focal ablative therapy in the management of prostate cancer in carefully selected cases. We have demonstrated good oncological results with minimal morbidity and a favourable sideeffect profile. 
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INTRODUCTION AND OBJECTIVES:
Although there is increasing interest in focal therapy for prostate cancer as an alternative treatment option to whole-gland therapy, it remains difficult to select eligible candidates. We sought to identify preoperative factors that can predict extensive disease after radical prostatectomy (RP) in potential candidates for hemi-ablative focal therapy.
METHODS: We identified 770 patients who were diagnosed with unilateral prostate cancer by biopsy, met the focal therapy consensus meeting criteria (PSA<15 ng/mL, clinical stage T1c-T2a, Gleason score 3+3 or 3+4), and had undergone RP at our institution between 2000 and 2014. Among these 770 patients, 98 had tumor maps from whole-mount slides and magnetic resonance imaging (MRI) data. Extensive disease was defined as having Gleason pattern 4 or 5 in bilateral lobes, extracapsular extension, seminal vesicle involvement, or lymph node involvement on the tumor map and RP pathology. Both lobes of the prostate were scored using the standardized 5-point Prostate Imaging Reporting and Data System version 2 on MRI. Extracapsular extension and seminal vesicle involvement were also scored using a 5-point scale. Preoperative characteristics including biopsy and MRI data were evaluated. Selected predictors of extensive disease were analyzed by multivariable logistic regression. Decision curve analysis was performed to evaluate the clinical utility of our model.
RESULTS: Among our cohort, 39 patients (40%; 95% CI 30%, 50%) had extensive disease. The Kattan nomogram score (p¼0.020) and a MRI extracapsular extension score 3 (p¼0.002) were independent predictors of extensive disease. Our model exhibited a discrimination of 0.698 after 10-fold cross-validation. However, decision curve analysis demonstrated that our multivariable model does not add value for threshold probabilities of having extensive disease below 20%, with no increase in net benefits compared to a treat-all strategy.
CONCLUSIONS: Although the variables in our model are significantly associated with extensive disease, it was not able to place patients into a low enough risk of extensive disease where hemi-ablative therapy would be indicated. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e939
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